N/A N=203 Microalbuminuria in Children With and Without Diabetes
Diabetes Mellitus
Primary: Number of Subjects With Normal Urinary Protein Excretion in Healthy and Diabetic Children, Assessed Over 1 Day. — 91; 112 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=130 Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
Diabetic Kidney Disease
Primary: Changes in Log-transformed Urinary Albumin-to-creatinine Ratio (UACR) at Week 12 — -0.10; -0.15; -0.53 Log(mg/g) — p=0.7953
N/A N=44 A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Alport Syndrome · Kidney Disease
Primary: Number of Subjects Developing Microalbuminuria During Study Period — 35 Participants
Phase 2 N=154 A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
Chronic Kidney Disease · Type 2 Diabetes Mellitus
Primary: Changes in Urine Albumin to Creatinine Ratio (UACR) — -64.6; 104.8 mg/g — p=0.279
Phase 3 N=1,056 Effect of Sulodexide in Early Diabetic Nephropathy
Diabetic Nephropathy
Primary: Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria — 39; 30 Participants
N/A N=27 Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
Microalbuminuria
Primary: Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio — 256.1; 376.2 Ratio
Phase 4 N=237 Shiga Microalbuminuria Reduction Trial-2
Type 2 Diabetes Mellitus · Hypertension
Primary: Reduction in Albuminuria — -5.5; -6.7 percentage of UACR change
Phase 2 N=415 A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
Type 2 Diabetes Mellitus and Microalbuminuria
Primary: Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12) — 0.152; -0.173…
N/A N=136 A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)
Hypertension
Primary: Number of Participants With Macroalbuminuria After 6 Months of Treatment — 7; 6 participants
N/A N=1,537 Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
Type 2 Diabetes Mellitus
Primary: Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and…
Phase 4 N=28 Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g
Phase 2 N=136 Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Albuminuria Absolute Value and Ratio to Baseline by Study Visit and Treatment Group — 705.72; 696.30; 758.22; 705.29 mg/g — p=1.000
Phase 2 N=17 Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
Kidney Disease · Albuminuria
Primary: The Primary Outcome Measure is Level of Albuminuria. — 927.9; 897.1 ratio
Phase 4 N=128 ARIA (Atacand Renoprotection In NephropAthy Pt.)
Non-diabetic Nephropathy With Hypertension
Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g
Phase 2 N=226 A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
Diabetic Nephropathy
Primary: Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 — 13.27; 5.02 percent (%)
N/A N=150 Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study
Diabetes
Primary: Compare the Pearson Correlation of Glycated Albumin (GA) and Fructosamine Within All Subjects With the Performance Goal of 0.8 — 0.7056; 0.5271 Pearson correlation…
Phase 3 N=360 MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment — -0.03; -0.63 Percentage of HbA1c — p=<0.0001
Phase 2 N=237 Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
Hyperlipidemia
Primary: Urinary Protein/Creatinine Ratio at Week 52 [LOCF] — 0.938; 1.082; 0.759 ratio
Phase 2 N=156 A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs — 24; 21; 22; 6 Participants
Phase 2 N=281 The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
Diabetic Nephropathy · Chronic Kidney Disease
Primary: Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine…
Phase 2 N=60 Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Hyperuricemia · Albuminuria · Type 2 Diabetes
Primary: Urinary Albumin to Creatinine Ratio (UACR) — -48.65; -15.31 Precent change
Phase 2 N=353 Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
Diabetes Mellitus
Primary: Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. — 1.016; 0.955; 0.874 mg/g
N/A N=2,711 TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium
Hypertension
Primary: Percentage of Patients With Controlled Blood Pressure — 46.1; 24.1 Percentage of patients — p=<0.0001
Phase 3 N=448 A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
Type 2 Diabetes Mellitus, CKD and Albuminuria
Primary: Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24 — -0.85; -0.27…
Phase 3 N=170 Renoprotection in Early Diabetic Nephropathy in Pima Indians
Diabetic Nephropathy
Primary: Number of Participants With Decline in GFR — 2; 2; 1; 4 participants
Phase 4 N=5,812 A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2 · Albuminuria
Primary: Progression of Albuminuria — 153.01; 99.80 Events per 1000 patient-year — p=<.0001
Phase 3 N=530 A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Diabetic Nephropathies · Coronary Artery Disease
Primary: iGFR at the End of the Wash-out Period — 61.2; 61.2 ml/min/1.73 m^2 — p=0.999
Phase 2 N=34 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Diabetic Nephropathy
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change
N/A N=80 Uric Acid and the Endothelium in CKD
Kidney Disease
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47
Phase 4 N=72 Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Diabetes Mellitus, Type 2
Primary: GFR (Glomerular Filtration Rate) Change After Treatment — 22; 1; 8; 0 ml/min/1.73m^2